PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies.
“We are pleased to welcome Kasra to our executive leadership team,” said James McArthur, PhD, President and Chief Executive Officer of PepGen. “He brings a rare depth of expertise in product and process development, coupled with a proven track record of CMC leadership extending across early-stage development through multiple successful global regulatory approvals. Kasra’s background advancing therapies for rare genetic disorders, along with his ability to navigate manufacturing and regulatory landscapes, will be instrumental as we progress our clinical programs through mid-stage development and beyond. We look forward to his contributions as we work to deliver potentially transformative therapies for people living with severe neuromuscular conditions.”
Dr. Kasraian joins PepGen from bluebird bio, where he held various roles of increasing responsibility. Most recently, he served as Senior Vice President, Quality, Regulatory Affairs, and CMC Sciences. Prior to this role, he served as Senior Vice President, Technical Development and Operations, where he played a central role in the approval and launch of three gene therapy products—SKYSONA™, ZYNTEGLO™, and LYFGENIA™.
Prior to bluebird bio, Dr. Kasraian led the Technical Operation, Quality, and Regulatory CMC functions at Zafgen, Inc. Previously, he held scientific and leadership roles at Biogen, Wyeth Biotech, Pfizer Inc., and Genetics Institute in the areas of formulation development, process development, technical services, manufacturing, and CMC management encompassing early phase development through commercialization for both small molecules and biologics. During his tenure at Biogen, the CMC team he led guided the submission and approval of 3 BLAs/MAAs.
Dr. Kasraian earned his PhD in Pharmaceutical Sciences and his BS in Chemical Engineering from the University of Kentucky.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter |The Mainstream formerly known as CIO News Whatsapp Channel | The Mainstream formerly known as CIO News Instagram
About us:
The Mainstream formerly known as CIO News is a premier platform dedicated to delivering latest news, updates, and insights from the tech industry. With its strong foundation of intellectual property and thought leadership, the platform is well-positioned to stay ahead of the curve and lead conversations about how technology shapes our world. From its early days as CIO News to its rebranding as The Mainstream on November 28, 2024, it has been expanding its global reach, targeting key markets in the Middle East & Africa, ASEAN, the USA, and the UK. The Mainstream is a vision to put technology at the center of every conversation, inspiring professionals and organizations to embrace the future of tech.
